"Today marks what we believe to be an important milestone for European patients with BBS and POMC/LEPR deficiencies ages 2 to 6, who now have the opportunity to address the severe and insatiable hunger and early onset obesity associated with their conditions at an early age," said Yann Mazabraud, Executive Vice President, Head of International at Rhythm Pharmaceuticals. "Early-onset obesity that goes untreated can manifest in multiple comorbidities and negatively affect quality of life and life expectancy. ...